Colorado Prescription Drug Affordability Board:
How New Upper Payment Limits Impact Prescribers & Patients

Monday, June 23
 6:00pm - 7:00pm MST
Registration required.

Register Now

The Colorado Prescription Drug Affordability Board will be the first state Board to consider upper payment limits on prescription medications, including Enbrel, Stelara, and Cosentyx. While this Board is tasked with making prescription drugs more affordable for patients, these payment limits are likely to reduce prescriber reimbursement and limit patient access.

Join Advocates for Compassionate Therapy Now, International Foundation for Autoimmune & Autoinflammatory Arthritis, CSRO, and Colorado BioScience Association to learn how these new payment limits may impact your practice and your patients. Speakers include: 

• Bridget Dandaraw-Seritt – Founder, Advocates for Compassionate Therapy Now (ACT Now)
• Tiffany Westrich-Robertson – CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)
• Harry L. Gewanter, MD, FAAP, MACR – Board of Directors, Coalition of State Rheumatology Organizations (CSRO)
• Amy Berenbaum Goodman – Vice President and Counsel, Policy + Advocacy, Colorado BioScience Association